by Admin Neo Lumina | Jul 17, 2025 | Press Release
NeoLumina BioScience Preparing to Begin a Phase 2 Clinical Trial of Innovative Psilocybin-Based Therapy for Binge Eating Disorder VANCOUVER, BRITISH COLUMBIA / July 17, 2025 / NeoLumina BioScience Inc., a pioneering clinical-stage biopharmaceutical company dedicated...
by Admin Neo Lumina | Jul 17, 2025 | Press Release
NeoLumina BioScience to Initiate Strategic Collaboration for Novel Psilocin Delivery System to Advance Mental Health Treatment VANCOUVER, BRITISH COLUMBIA / July 17, 2025/ NeoLumina BioScience Inc., a pioneering clinical-stage biopharmaceutical company dedicated to...
by Admin Neo Lumina | Sep 28, 2023 | Press Release
NeoLumina Bioscience In-Licenses Clinical-stage Psilocybin Product Candidate from Filament Health for Eating Disorders PEX010 expands NeoLumina’s psychedelic product pipeline. Funding activity in process to advance clinical development. VANCOUVER, BRITISH COLUMBIA,...
by Admin Neo Lumina | Aug 28, 2023 | Press Release
NeoLumina Bioscience Advancing Development of Proprietary Psychedelic-based Therapeutic Medicines Funding activity initiated to advance lead psilocybin-based product candidate into human studies VANCOUVER, BC (August 30, 2023) – NeoLumina Bioscience Inc. (“NeoLumina”...
